Internal restructuring
Location of affected unit(s)
Denmark, China
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.1 - Manufacture of basic pharmaceutical products

400 jobs
Number of planned job losses
Job loss
Announcement Date
18 September 2018
Employment effect (start)
1 October 2018
Foreseen end date


The Danish pharma group Novo Nordisk has announced to cut 400 positions in its research and development (R&D) services in Denmark and China. Novo Nordisk, which is the world’s biggest insulin maker, has decided to refocuses its R&D efforts on 'transformational biological and technological innovation'. Therefore, administrative staff, laboratory technicians and scientists working in the R&D services will be laid off in Denmark and China. But Novo Nordisk will also hire specialists in areas such as computational biology, stem cells and new disease areas (but the number of job creations is not known). The company has decided to reorganise the structure of its R&D organisation, creating internally four research units based in Denmark, the US and the UK. These units will operate as satellites of the company’s central R&D function. Novo Nordisk employs more than 43,000 people worldwide.



Eurofound (2018), Novo Nordisk, Internal restructuring in World, factsheet number 95497, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/95497.